Kymera Therapeutics, Inc. announced on October 9, 2024, that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for KT-621. KT-621 is a potent, selective, oral degrader of STAT6, an essential transcription factor in the IL-4/IL-13 signaling pathways.
The company expects to initiate dosing in a Phase 1 clinical trial in healthy volunteers in October 2024. Data from this Phase 1 study is anticipated in the first half of 2025. This clearance marks KT-621 as the first STAT6 targeted medicine to advance into clinical evaluation.
Kymera believes KT-621 has the potential to combine the complete pathway blockade of upstream biologics with the convenience of oral administration. This approach aims to transform the current treatment paradigm for atopic and allergic diseases, including atopic dermatitis, asthma, and chronic obstructive pulmonary disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.